A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial

BACKGROUND: Every year in Europe about 25,000 infants are born extremely preterm. These infants have a 20% mortality rate, and 25% of survivors have severe long-term cerebral impairment. Preventative measures are key to reduce mortality and morbidity in an extremely preterm population. The primary o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyttel-Sorensen, Simon, Austin, Topun, van Bel, Frank, Benders, Manon, Claris, Olivier, Dempsey, Eugene, Fumagalli, Monica, Greisen, Gorm, Grevstad, Berit, Hagmann, Cornelia, Hellström-Westas, Lena, Lemmers, Petra, Lindschou, Jane, Naulaers, Gunnar, van Oeveren, Wim, Pellicer, Adelina, Pichler, Gerhard, Roll, Claudia, Skoog, Maria, Winkel, Per, Wolf, Martin, Gluud, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680969/
https://www.ncbi.nlm.nih.gov/pubmed/23782447
http://dx.doi.org/10.1186/1745-6215-14-120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680969/
https://www.ncbi.nlm.nih.gov/pubmed/23782447
http://dx.doi.org/10.1186/1745-6215-14-120

Ejemplares similares